Biospecifics Tech Cp (BSTC) 41.69 $BSTC BioSpecifics

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 4:14 AM

Biospecifics Tech Cp (BSTC) 41.69 $BSTC

BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
PR Newswire - Mon Jun 13, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
PR Newswire - Tue May 31, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum." The data show that highly purified CCH can reduce the stiffness of human uterine fibroids ex-vivo and potentially decrease their size.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.
BSTC: 41.69 (+1.87)

New Strong Sell Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:48AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AIXG: 5.83 (-0.02), BSTC: 41.69 (+1.87), AZZ: 60.12 (+1.09), ASB: 17.11 (+0.22), AHT: 5.56 (+0.27)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01), RPRX: 1.73 (+0.05)

Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 41.69 (+1.87), JAZZ: 139.88 (+1.40), ARQL: 1.74 (+0.08), APRI: 0.39 (+0.01)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.58 (+0.07), ENDP: 17.42 (+0.14), BSTC: 41.69 (+1.87), ARQL: 1.74 (+0.08)

ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 41.69 (+1.87), INCY: 85.70 (+2.17), ARQL: 1.74 (+0.08), ARIA: 7.51 (+0.17)

BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
PR Newswire - Tue May 03, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Tuesday, May 10, 2016 to report its first quarter 2016 financial results and to provide a corporate update.
BSTC: 41.69 (+1.87)

Why BioSpecifics Technologies (BSTC) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 7:33AM CDT
BioSpecifics Technologies (BSTC) looks like an interesting choice for investors, as it is seeing solid estimate revisions and belongs to a great industry.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Present at the 15th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 06, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:40 a.m. ET in New York, NY.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2015 Financial Results
PR Newswire - Mon Mar 14, 6:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Present at the 28th Annual ROTH Conference
PR Newswire - Tue Mar 08, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 28th Annual ROTH Conference on Tuesday, March 15, 2016 at 12:30 p.m. PT in Dana Point, CA.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Report Fourth Quarter and Full Year 2015 Financial Results on Monday, March 14, 2016
PR Newswire - Mon Mar 07, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to report its fourth quarter and full year 2015 financial results and to provide a corporate update.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Present at the Noble Financial Capital Markets' NobleCon12
PR Newswire - Tue Jan 12, 4:00PM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Noble Financial Capital Markets' NobleCon12 on Tuesday, January 19, 2016 at 9:30 a.m. ET in Sandpiper Bay, FL.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. to Present at the Stifel 2015 Healthcare Conference
PR Newswire - Mon Nov 16, 7:00AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, announced today that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Stifel 2015 Healthcare Conference.
BSTC: 41.69 (+1.87)

BioSpecifics Technologies Corp. Reports Third Quarter 2015 Financial Results
PR Newswire - Mon Nov 09, 6:30AM CST
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2015 and provided a corporate update.
BSTC: 41.69 (+1.87)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NAPCO Security's Innovative Push at ISC East 2026

NAPCO's New Showcase at ISC East 2026 Let's dive into NAPCO Security Technologies' latest development, because these folks are taking the stage at the ISC East 2026, one of the big kahunas in security trade shows. Happening on November 4th and 5th at the Jacob Javits Center, the booth near the main entrance will be the place to catch the latest from this New York outfit,...

FirstService Ups the Ante with Stylish Jacksonville Office

A New Chapter for FirstService Residential Picture this: a property management powerhouse dialing up their Jacksonville operations with a shiny new office move. FirstService Residential, North America's big shot in property management, has swapped location to a swish setup on Southpoint Drive South in Jacksonville, Florida, aiming to supercharge collaboration and give a...

York Space Systems Faces Critical Lawsuit Deadline

Turbulence in the Satellite Markets When York Space Systems launched its flashy IPO earlier this year, investors lined up in droves, eyes gleaming at the promise of satellite-driven riches. But now, it feels like that promising start shattered faster than a cheap rocket. York, known for its bread-and-butter reliance on federal contracts, primarily with the U.S. Department...

Rising Demand for Natural Fibres: Woolmark's Bold Move

A Shift Toward Nature-Driven Choices There's something brewing in the fashion world that signals a deeper shift—a movement toward fibers that feel real, fibers that nature and time have refined. Recent Ipsos research commissioned by Woolmark has laid bare the growing consumer preference across major markets, with a distinct swing towards natural fibers, leaving...

Proxy Season 2026: Proposals Drop But Support Rises

An Unexpected Twist in Proxy Season The corporate governance scene for 2026's proxy season has thrown its share of curveballs. Shareholders are rallying their support behind proposals, even as the volume of those proposals tumble like a bad penny drop. Broadridge's recent ProxyPulse report shakes up the scene, getting us all to take a closer look at what's really...

Data Center Piping Surges With AI Cooling to $4.5B

Liquid Cooling Revolutionizes Data Center Infrastructure Gotta hand it to the tech world, when it decides to shift, it shifts hard and fast. The data center piping market isn't just keeping up—it's sprinting. The move towards liquid-cooled AI setups isn’t just a trend; it’s a defining transformation. With a projected explosion to a $4.5 billion market by 2035, you...

Elanco's Strategic Shift: Jamie Preston Takes the Helm

Elanco's Bold HR Transition: A New Leader Steps Up Well, here's a shake-up that might just turn a few heads in the corporate world. Elanco Animal Health, the outfit with the ticker NYSE:ELAN that many have their eyes on, is shuffling its HR deck, bringing in Jamie Preston from Eli Lilly to take charge as the new Chief People Officer. Mark November 3rd on your calendars;...

Revolutionizing Textiles: Touchscreen Garments Emerge

Picture a world where your shirt does more than just cover your back. Bingo, folks—smart textiles have taken center stage with groundbreaking technology that melds touchscreens with fabric, and the brains behind it hail from the National University of Singapore (NUS). It's not just about slapping a few LEDs onto a vest. We're talking about clothing that can display...

Prospanica Summit 2026: Envisioning More Opportunities Ahead

The Road to Envisioning 'Más': A Dive into the Future Let's break down what's ahead with the 2026 Prospanica Summit—a collision of ambition and opportunity set to strike at Marina Del Rey. It's a Saturday—November 7th to be exact—when all this goes down, aiming to shake up the aspirations of Hispanic MBAs and business pros from coast to coast. Think MBAs,...

Cystic Fibrosis Market: Emerging Therapies Boost Growth

The landscape of cystic fibrosis treatment is on the cusp of a seismic shift, promising new therapies poised to redefine patient care and market dynamics. As we stand at the intersection of innovation and opportunity, the impending transformation is fueled by groundbreaking therapies, increased healthcare spending, and a stronger push for personalized medicine. The Winds...